|
WO02085360A1
|
|
Optimized procedures for the manufacture of paroxetine salts
|
|
WO02076940A2
|
|
Process for preparing arylpiperidine carbinol intermediates and derivatives
|
|
US6566368B2
|
|
Apomorphine-containing dosage form for ameliorating male erectile dysfunction
|
|
US6660298B1
|
|
Paroxetine tablets and capsules
|
|
EP1180021A1
|
|
Regimen and kit for amelioration of premature ejaculation
|
|
AU3744800A
|
|
Controlled release of sildenafil delivered by sublingual or buccal administration
|
|
EP1140832A1
|
|
Process for preparing arylpiperidine carbinol intermediates and derivatives
|
|
US6503927B1
|
|
Amorphous paroxetine composition
|
|
US6087362A
|
|
Apomorphine and sildenafil composition
|
|
US5994363A
|
|
Amelioration of apomorphine adverse effects
|
|
WO9909828A1
|
|
Method for amelioration of social phobia
|
|
US6121276A
|
|
Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
|
|
AU7265898A
|
|
Controlled release of drugs delivered by sublingual or buccal administration
|
|
US5945117A
|
|
Treatment of female sexual dysfunction
|
|
US6638948B1
|
|
Amorphous paroxetine composition
|
|
US5888534A
|
|
Controlled release of drugs delivered by sublingual or buccal administration
|
|
US5672612A
|
|
Amorphous paroxetine composition
|
|
US5830500A
|
|
Low dose fluoxetine tablet
|
|
US5624677A
|
|
Controlled release of drugs delivered by sublingual or buccal administration
|
|
MX9604981A
|
|
Dosage forms and method for ameliorating male erectile dysfunction.
|
